Skip to Content

Posts tagged with "Infectious Diseases"

  • Infectious Diseases

    New Antibiotics, Potential and (Nearly) Actual

    Some antibiotic news today: first off, there’s a new multinational collaboration (CARB-X) to work on drug-resistant bacteria. Among other things, it’ll be giving grants to small companies in the US and Europe who are working in the area. They’re especially targeting new varieties of compounds, rather than variations on existing sc… Read More
  • Business and Markets

    Merck Loses. Boy, Does Merck Ever Lose.

    The court case between Merck and Gilead has taken the path that it appeared to be heading down after a Merck employee’s testimony was called into question: the judge has thrown out the $200 million dollar patent award to Merck. All that work for nothing, and all because the testimony of a key witness fell apart. Read More
  • Drug Assays

    Drugs from Fungi, Or Fungi As Drugs?

    This is an interesting article, but a lay reader would probably not realize how many important things are left out of it. It’s about a mushroom grower (Tradd Cotter) who’s been studying ways to protect his desired fungi against other pathogens, and who has an idea about extending this work to human therapies. He’s co-culturing… Read More
  • Academia (vs. Industry)

    Want Your Compounds Tested Against Pathogens For Free?

    I’d like to help publicize what seems like a very worthwhile effort, funded by the University of Queensland and the Wellcome Trust: the Community for Open Antimicrobial Drug Discovery (CO-ADD). Here’s a writeup on them in Nature – what they’re doing is taking compounds from all sources and screening them against panels of i… Read More
  • Chemical News

    Antibiotics From Scratch

    There’s a lot more antibiotic news to cover this week, and I thought I’d start out with some very high-level organic chemistry. This paper from the Myers lab at Harvard is really nice stuff: they’re looking at macrolide antibiotics (such as erythromycin) and trying to find ways to make large number of variations of them… Read More
  • Infectious Diseases

    Unclean Hands?

    Well, this doesn’t look good: reports are that the Gilead/Merck hepatitis C inhibitor patent case may be heading back into court under accusations that one of Merck’s patent lawyers (a former med-chemist) lied under oath. The scientist involved, Phil Durette, already had some problems during his testimony the first time around: At tria… Read More
  • Alzheimer's Disease

    Microbial Alzheimer’s: The Arguing Continues

    The Journal of Alzheimer’s Disease has published an editorial, signed by thirty-one researchers from institutions across several continents, calling on a re-evaluation of the disease’s origins: We are researchers and clinicians working on Alzheimer’s disease (AD) or related topics, and we write to express our concern that one particu… Read More
  • Business and Markets

    A (Busy) Day in the Life

    I’d like to recommend this article by Lisa Jarvis at C&E News – she’s following along with Forge Therapeutics, a small startup specializing in metalloprotease inhibitors, as they make it through a day at the recent J. P. Morgan conference in San Francisco. It’s an accurate and realistic look at a world that not everyone… Read More
  • Infectious Diseases

    Fun With Priority Review Vouchers

    So in that last post, I mentioned a Priority Review Voucher as a likely reason for Marin Shkreli’s latest machinations, and that makes me think that I should explain what the heck a Priority Review Voucher is, since it’s an obscure topic if you’re not into the ins and outs of regulatory drug approval. It’s… Read More
  • Business and Markets

    Shkreli’s Chagas Maneuver

    In case you’ve been wondering what Martin Shkreli has been up to, here’s a look at his recent appearance at a meeting put on by the folks at Forbes. “Unrepentant” would be an appropriate adjective, although I can think of some others, along with some richly descriptive nouns. He has been backing out of his statements… Read More